Clinical Trial Update: Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

View source ↗

Summary

This clinical trial update reports real-world outcomes for patients with relapsing-remitting multiple sclerosis who switch to Tecfidera after treatment with Nat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)
• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED